No surgery nor hospital stay required. Cost of ultrasound treatment can range from Rs 60,000 to Rs 1,00,000
A blood-less, operation free ultrasonic system to completely remove non-cancerous tumours or fibroids in the uterus of women without causing pain has been installed in Jaslok Hospital, Mumbai.
The new device utilizes GE Magnetic Resonance – guided Focused Ultrasound Surgery (MrgFUS) technology to destroy fibroids in the uterus without cutting open the body nor spilling a drop blood.
MrgFUS ultrasound device in Jaslok hospital, Mumbai makes use of high intensity ultrasound waves to non-invasively for bringing about total destruction of all non-cancerous tumours and growths in the uterus.
Fibroids in the uterus is a common gynaecological condition among women. Uterine fibroids affect large numbers of women, causing a variety of symptoms such as pelvic pain, incontinence and swelling of the abdomen.
The most common treatment for fibroids is hysterectomy, or removal of the uterus through an operation. The surgical procedure to remove operation involves a stay in hospital and up to six weeks of recovery time.
The MRgFUS ultrasound device is considered a major breakthrough in this context as it destroys fibroids without causing damage to surrounding tissues.
So it could be used as a common alternative to removal of a uterus or hysterectomy.
Moreover, the MrgFUS ultrasound treatment is carried out as an outpatient procedure and no hospital stay is required. It has a shorter recovery time than hysterectomy and can help women to return much more quickly to normal daily activities.
The ultrasound treatment is associated with minimal risks and complications, requires no overnight hospital stay and allows most patients to return to work and their normal activities in one to two days.
A treatment session using the MrgFUS ultrasound to remove fibroids lasts up to three hours. No overnight stay is required for the patient.
The cost of treatment can range from Rs 60,000 to Rs 1,00,000, according to the nature of the fibroids.
The ExAblate 2000 system uses the breakthrough MRgFUS technology that combines MRI to visualize tissues in the body, plan the treatment and monitor, in real time, treatment outcome and high intensity focused ultrasound to heat or thermally ablates diseased tissue.
MR thermal feedback, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumour is fully treated without damaging the surrounding tissue.
The MRgFUS technology – the ExAblate 2000, developed by Insightec is the only the US Food and Drug Administration (FDA) approved system for treatment of uterine fibroids and works exclusively with GE 1.5T and 3.0T Magnetic Resonance Imaging (MRI) systems.
The technology is also CE approved for pain palliation treatment for bone metastases, and clinical trials are under way to determine if the technology could be an alternative treatment for a number of cancers including breast, brain, liver cancer, and prostate, reports said.